DEXAMETHASONE, CARFILZOMIB, DEXAMETHASONE, DEXAMETHASONE, CC-92480 clinical trials

A Phase 2, single arm Multicenter, Study testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM). (MEZI-KD)

This study is looking at a new combination of medicines - mezigdomide, carfilzomib, and dexamethasone - for people with multiple myeloma that has come back or isn't responding to other treatments. It wants to see how well this new treatment works.